FDA does U-turn, will review Moderna’s mRNA flu shot after shocking rejection
Summary
The article reports that the FDA reversed a prior decision and will review Moderna’s mRNA flu vaccine after concerns about the initial trial design and political influence. It describes the Type A meeting and potential age-based approvals, and notes criticisms about anti-vaccine sentiment affecting biotech investment and policy.